ATE466883T1 - Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten - Google Patents

Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten

Info

Publication number
ATE466883T1
ATE466883T1 AT98945101T AT98945101T ATE466883T1 AT E466883 T1 ATE466883 T1 AT E466883T1 AT 98945101 T AT98945101 T AT 98945101T AT 98945101 T AT98945101 T AT 98945101T AT E466883 T1 ATE466883 T1 AT E466883T1
Authority
AT
Austria
Prior art keywords
plaques
monoclonal antibodies
protease activity
protein component
pathological conditions
Prior art date
Application number
AT98945101T
Other languages
English (en)
Inventor
Silvia Trasciatti
Sergio Rosini
Original Assignee
Abiogen Pharma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma Spa filed Critical Abiogen Pharma Spa
Application granted granted Critical
Publication of ATE466883T1 publication Critical patent/ATE466883T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98945101T 1997-07-30 1998-07-28 Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten ATE466883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001826A IT1293511B1 (it) 1997-07-30 1997-07-30 Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
PCT/EP1998/004706 WO1999006066A2 (en) 1997-07-30 1998-07-28 Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions

Publications (1)

Publication Number Publication Date
ATE466883T1 true ATE466883T1 (de) 2010-05-15

Family

ID=11377678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945101T ATE466883T1 (de) 1997-07-30 1998-07-28 Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten

Country Status (17)

Country Link
US (1) US6387674B1 (de)
EP (1) EP0996463B1 (de)
JP (1) JP2001511369A (de)
CN (1) CN1268175A (de)
AT (1) ATE466883T1 (de)
AU (1) AU741368B2 (de)
CA (1) CA2299442C (de)
CY (1) CY1110128T1 (de)
DE (1) DE69841653D1 (de)
DK (1) DK0996463T3 (de)
ES (1) ES2340892T3 (de)
IL (1) IL134142A0 (de)
IT (1) IT1293511B1 (de)
NO (1) NO329769B1 (de)
NZ (1) NZ502527A (de)
PT (1) PT996463E (de)
WO (1) WO1999006066A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
HK1054865B (zh) * 2000-02-21 2007-06-01 H. Lundbeck A/S 下调淀粉状蛋白的新方法
CA2400559C (en) 2000-02-24 2012-05-01 Washington University Humanized antibodies that sequester .alpha..beta. peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6613505B2 (en) 2001-04-12 2003-09-02 Bioresource International, Inc. Composition and method for destruction of infetious prion proteins
US7318923B2 (en) 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US7771722B2 (en) 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RS53291B (sr) 2005-12-12 2014-08-29 Ac Immune S.A. Beta 1-42 specifična monoklonska antitela sa terapeutskim svojstvima
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2842967B1 (de) 2007-01-18 2016-11-30 Eli Lilly and Company Pegyliertes Amyloid-beta-Fab
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
AU2008311367B2 (en) * 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011005481A (es) 2008-11-25 2011-08-17 Biogen Idec Inc Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
US8317737B2 (en) * 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8246565B2 (en) 2009-02-25 2012-08-21 The Invention Science Fund I, Llc Device for passively removing a target component from blood or lymph of a vertebrate subject
US8454547B2 (en) 2009-02-25 2013-06-04 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
MY171761A (en) 2012-03-14 2019-10-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
ES2971045T3 (es) 2015-07-06 2024-06-03 Regeneron Pharma Moléculas multiespecíficas de unión a antígeno y usos de las mismas
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
KR20250140631A (ko) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 항-cd63 항체, 콘쥬게이트, 및 이의 용도
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US6156541A (en) * 1995-07-21 2000-12-05 The Board Of Regents Of The University Of Nebraska Compositions and methods for catalyzing hydrolysis of HIV gp120

Also Published As

Publication number Publication date
NO20000396L (no) 2000-03-29
AU9255398A (en) 1999-02-22
CA2299442A1 (en) 1999-02-11
IL134142A0 (en) 2001-04-30
EP0996463A2 (de) 2000-05-03
ES2340892T3 (es) 2010-06-10
NO20000396D0 (no) 2000-01-26
NZ502527A (en) 2003-01-31
IT1293511B1 (it) 1999-03-01
NO329769B1 (no) 2010-12-13
AU741368B2 (en) 2001-11-29
WO1999006066A2 (en) 1999-02-11
CA2299442C (en) 2011-06-21
CY1110128T1 (el) 2015-01-14
CN1268175A (zh) 2000-09-27
DE69841653D1 (de) 2010-06-17
PT996463E (pt) 2010-05-17
DK0996463T3 (da) 2010-08-09
WO1999006066A3 (en) 1999-04-29
ITMI971826A1 (it) 1999-01-30
US6387674B1 (en) 2002-05-14
JP2001511369A (ja) 2001-08-14
EP0996463B1 (de) 2010-05-05

Similar Documents

Publication Publication Date Title
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
HUP0103758A2 (hu) Neurotróf faktorok
DE60023148D1 (de) Amine and amide als ligande für den neuropeptid-y y5 rezeptor, und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE355293T1 (de) Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
DE69818606D1 (de) Hydrierung von Nitrilen zur Herstellung von Aminen
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
ATE227343T1 (de) Protease und verwandte dns-verbindungen
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
EP1030819A4 (de) Immunogene konjugierte polypeptide für die behandlung von herpes-simplex virus
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69931976D1 (de) Verfahren zur Herstellung von Aminophosphinen und Aminophosphinoxiden, Zwischenprodukte dafür
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0996463

Country of ref document: EP

REN Ceased due to non-payment of the annual fee